Quantcast

Latest Organofluorides Stories

2014-09-01 23:01:31

The Firm is evaluating potential Lipitor lawsuits on behalf of individuals who allegedly developed Lipitor diabetes injuries after taking the cholesterol-lowering statin drug. New York, NY (PRWEB) September 01, 2014 More than 200 Lipitor lawsuit (http://www.thelipitorlawsuit.com/) filings have been added to a federal litigation that continues to progress in the U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. A federal Case List published on August 15th...

2014-08-31 04:21:07

Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial TARRYTOWN, New York and PARIS, Aug. 31, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.(...

2014-08-31 04:20:55

- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y., Aug. 31, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia....

2014-08-29 16:21:39

DUBLIN, Ireland, August 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/ljjdcg/global) has announced the addition of the "Global Trifluoroacetic Acid Industry Report 2014" [http://www.researchandmarkets.com/research/ljjdcg/global ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Global Trifluoroacetic Acid Industry Report 2014 is a professional and in-depth study on the current state of...

2014-08-27 23:03:24

ReportsnReports.com adds “2014 Market Research Report on Global and China Trifluoroacetic Acid Industry” market research report to its store. Dallas, TX (PRWEB) August 27, 2014 The Global and China Trifluoroacetic Acid Industry is a professional and in-depth study on the current state of the Trifluoroacetic Acid industry in Global and China. The report provides a basic overview of the industry, including definitions, applications and industry chain structure. Global market analysis...

2014-08-26 23:03:41

The Firm is actively filing Risperdal lawsuits on behalf of men and boys who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication. New York, New York (PRWEB) August 26, 2014 As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) mount in courts throughout the U.S., Bernstein Liebhard LLP notes the publication a new report that raises troubling questions about the use of psychotropic drugs among children in California’s...

2014-08-25 08:28:30

Multimedia assets associated with the below announcement are now available. Assets include: b-roll footage, corporate sound bites, product images and additional information. Please click: http://www.multivu.com/players/English/7197331-viiv-healthcare-vhc-triumeq-fda-approval LONDON, Aug. 25, 2014 /PRNewswire/ -- On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the...

2014-08-22 16:23:16

LONDON, Aug. 22, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside...

2014-08-18 23:02:59

The anti-cancer drug Xalkori® is being investigated by the ECOG-ACRIN Cancer Research Group in E4512, a phase III trial. Philadelphia, PA (PRWEB) August 18, 2014 People diagnosed with early-stage non-squamous non-small cell lung cancer whose tumors have an altered ALK gene now have the opportunity to participate in a new phase III clinical trial, ECOG-ACRIN announced today. The trial will determine if Xalkori® (generic name crizotinib, an ALK-inhibitor), when used after...

2014-08-16 23:02:22

The Firm is representing numerous clients in Risperdal lawsuits that allege gynecomastia, or male breast development, due to their use of the antipsychotic drug. New York, NY (PRWEB) August 16, 2014 A Risperdal (http://www.lawreward.com/risperdal/) meeting is scheduled to take place next month in the Philadelphia Court of Common Pleas, where hundreds of lawsuits over the antipsychotic medication are continuing to move forward, Bernstein Liebhard LLP reports. According to a Calendar...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related